CL2019001208A1 - Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado. - Google Patents

Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado.

Info

Publication number
CL2019001208A1
CL2019001208A1 CL2019001208A CL2019001208A CL2019001208A1 CL 2019001208 A1 CL2019001208 A1 CL 2019001208A1 CL 2019001208 A CL2019001208 A CL 2019001208A CL 2019001208 A CL2019001208 A CL 2019001208A CL 2019001208 A1 CL2019001208 A1 CL 2019001208A1
Authority
CL
Chile
Prior art keywords
crenolanib
treat
patient
flt3
proliferative disorders
Prior art date
Application number
CL2019001208A
Other languages
English (en)
Inventor
Vinay K Jain
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of CL2019001208A1 publication Critical patent/CL2019001208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN INCLUYE MÉTODOS PARA TRATAR UN TRASTORNO PROLIFERATIVO CON FLT3 MUTADO QE COMPRENDE: MEDIR LA EXPRESIÓN DE UN FLT3 MUTADO Y UNA O MÁS ANORMALIDADES GENÉTICAS EN UNA MUESTRA OBTENIDA DE UNA MUESTRA DEL TUMOR OBTENIDA DEL PACIENTE, EN DONDE LA PRESENCIA DE LA UNA O MÁS ANORMALIDADES GENÉTICAS INDICA QUE EL PACIENTE TIENE UN MAL PRONÓSTICO; Y ADMINISTRAR AL PACIENTE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE CRENOLANIB O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, EN DONDE EL CRENOLANIB AUMENTA UNA PROBABILIDAD DE SUPERVIVENCIA DEL PACIENTE QUE TIENE EL FTL3 MUTADO Y LA UNA O MÁS ANORMALIDADES GENÉTICAS, EN DONDE EL CRENOLANIB, COMO SE MUESTRA A CONTINUACIÓN, SE ADMINISTRA A UN SUJETO QUE SUFRE DE DICHO TRASTORNO.
CL2019001208A 2016-11-02 2019-05-02 Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado. CL2019001208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416475P 2016-11-02 2016-11-02
US15/799,684 US11078541B2 (en) 2016-11-02 2017-10-31 Crenolanib for treating FLT3 mutated proliferative disorders associated mutations

Publications (1)

Publication Number Publication Date
CL2019001208A1 true CL2019001208A1 (es) 2019-07-26

Family

ID=62020370

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001208A CL2019001208A1 (es) 2016-11-02 2019-05-02 Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado.

Country Status (19)

Country Link
US (2) US11078541B2 (es)
EP (1) EP3359155A4 (es)
JP (2) JP2019532011A (es)
KR (2) KR20200079351A (es)
CN (1) CN108778276A (es)
AU (1) AU2017353925A1 (es)
BR (1) BR112019008762A2 (es)
CA (1) CA3024012A1 (es)
CL (1) CL2019001208A1 (es)
CO (1) CO2019005466A2 (es)
EA (1) EA201991078A1 (es)
HK (1) HK1257195A1 (es)
IL (1) IL266303A (es)
MX (1) MX2019005008A (es)
PE (1) PE20191238A1 (es)
PH (1) PH12019500965A1 (es)
SG (1) SG11201903889TA (es)
WO (1) WO2018085292A1 (es)
ZA (1) ZA201903089B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
EP3856173A4 (en) * 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN110531016B (zh) * 2019-09-05 2021-08-31 合肥诺明药物安全研究有限公司 一种hyml-122血药浓度定量分析方法
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11524006B2 (en) * 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN112921091B (zh) * 2021-03-16 2022-01-21 南京先声医学检验实验室有限公司 Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
KR20090087139A (ko) 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
US6686362B2 (en) 2001-12-27 2004-02-03 Theravance, Inc. Indolinone derivatives
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
KR100787649B1 (ko) 2003-06-24 2007-12-21 화이자 프로덕츠 인크. 1-[(벤조이미다졸-1-일)퀴놀린-8-일]피페리딘-4-일아민유도체의 제조 방법
ES2673603T3 (es) * 2009-04-06 2018-06-25 Vanda Pharmaceuticals Inc. Método de tratamiento basado en polimorfismos del gen KCNQ1
CA2867375A1 (en) * 2012-03-12 2013-09-19 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
KR20140040594A (ko) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 돌연변이체 c-kit의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ

Also Published As

Publication number Publication date
US20210324481A1 (en) 2021-10-21
PH12019500965A1 (en) 2019-12-02
WO2018085292A1 (en) 2018-05-11
MX2019005008A (es) 2019-09-10
SG11201903889TA (en) 2019-05-30
JP2019532011A (ja) 2019-11-07
JP2022071099A (ja) 2022-05-13
CO2019005466A2 (es) 2019-07-31
KR20200079351A (ko) 2020-07-02
CA3024012A1 (en) 2018-05-11
CN108778276A (zh) 2018-11-09
HK1257195A1 (zh) 2019-10-18
US11078541B2 (en) 2021-08-03
US20180117031A1 (en) 2018-05-03
EP3359155A4 (en) 2019-05-22
BR112019008762A2 (pt) 2019-07-16
IL266303A (en) 2019-06-30
AU2017353925A1 (en) 2018-09-27
PE20191238A1 (es) 2019-09-11
KR20180074792A (ko) 2018-07-03
ZA201903089B (en) 2019-12-18
EP3359155A1 (en) 2018-08-15
EA201991078A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
CL2019001208A1 (es) Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado.
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CR20190311A (es) Composiciones para tratar afecciones inflamatorias
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
CU20170014A7 (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2017004983A (es) Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
SV2018005730A (es) Biomarcadores para copanlisib
CL2017000050A1 (es) Terapia de combinación para el cáncer
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
CY1120278T1 (el) Συστημα χορηγησης φαρμακου για χρηση στη θεραπεια ή στη διαγνωση νευρολογικων διαταραχων
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
Lifeng et al. Research progress on status quo of quality of life of the elderly in pension institutions and countermeasures.
EA201691562A2 (ru) Фильтры для инфузионных наборов